Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Bullous Pemphigoid
CTR20220314Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Benralizumab arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy endpoint at Week 36. Started Feb 2022; status: terminated.
02
Drugs
benralizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on CTR20220314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220314.